GSK Is Breathing Easier On Advair Labeling, Expects Sales To Rebound
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline has increased the number of sales reps behind the long-acting beta antagonist to correct "labeling misperceptions."